Antiviral Agents
6
0
1
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
50.0%
3 terminated out of 6 trials
40.0%
-46.5% vs benchmark
17%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Antiviral Long Acting Drugs Landing in People Living With HIV
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.